Hi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal first quarter, leading to a sharp earnings surprise and large revenue growth.

< ?DART(15);?> With a gain of only around 3.8%, HITK is a top-performing Zacks #1 Rank company today. Volume is at 514,000, versus the daily average of 586,000.

HITK is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. It specializes in difficult-to-manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products.

The company is part of the Medical-Generic Drugs industry. There is only 1 other name from that space on today's 218-stock Zacks #1 Rank List, and that is Impax Laboratories, Inc. (IPXL).

Strong Fiscal First Quarter

In early September, HITK released its fiscal first quarter report, which included earnings per

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

PWRM, SHMN, MRK, TSPG, AQNM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Monday September 28, 2009, are:

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM’s NuroPro PD test was developed to help clinicians distinguish patients with Parkinson’s disease from “normal” individuals and patients with other neurological disorders. The NuroPro PD test, developed by Power3, utilizes a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability that a

...

Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with

...

By Martin Hutchinson Contributing Editor With sky-high growth potential, China and India are the two markets no investor can afford to miss out on. But that doesn’t mean they’re impervious to market turbulence, and in times of trouble, India is the more reliable investment. No doubt, both countries’ markets are suffering this year, with China’s Shanghai A Index down 50%, and India’s Sensex Index down 25%.  It’s no secret that India is struggling with both a growing budget deficit and mounting inflationary pressure. But China has problems too – it’s just hiding them under the carpet until the Olympics are over. That’s why, for me at least, the investment decision is clear – I’ll buy the country whose problems are out in the open and already reflected in stock prices. China’s Pending Credit Crunch China’s inflation has been quiescent recently. It declined from 8.7% ...